Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Psychiatry Reports
Published in: Current Psychiatry Reports 11/2015

01-11-2015 | Women's Mental Health (CN Epperson, Section Editor)

Substance Use in the Perinatal Period

Authors: Ariadna Forray, Dawn Foster

Published in: Current Psychiatry Reports | Issue 11/2015

Login to get access

Abstract

Perinatal substance use remains a major public health problem and is associated with a number of deleterious maternal and fetal effects. Polysubstance use in pregnancy is common and can potentiate adverse maternal and fetal outcomes. Tobacco is the most commonly used substance in pregnancy, followed by alcohol and illicit substances. The treatments for perinatal substance use are limited and consist mostly of behavioral and psychosocial interventions. Of these, contingency management has shown the most efficacy. More recently, novel interventions such as progesterone for postpartum cocaine use have shown promise. The purpose of this review is to examine the recent literature on the use of tobacco, alcohol, cannabis, stimulants, and opioids in the perinatal period, their effects on maternal and fetal health, and current treatments.
Literature
1.
United States Department of H, Human Services. Substance A, Mental Health Services Administration. Center for Behavioral Health S, Quality. National Survey on Drug Use and Health, 2012. Inter-university Consortium for Political and Social Research (ICPSR) [distributor]. 2013.
2.
Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996–1998. Obstet Gynecol. 2003;101:374–9.PubMedCrossRef
3.
Howell EM, Heiser N, Harrington M. A review of recent findings on substance abuse treatment for pregnant women. J Subst Abuse Treat. 1999;16:195–219.PubMedCrossRef
4.
Forray A, Merry B, Lin H, Ruger JP, Yonkers KA. Perinatal substance use: a prospective evaluation of abstinence and relapse. Drug Alcohol Depend. 2015;150:147–55.PubMedCrossRef
5.
Salihu HM, Wilson RE. Epidemiology of prenatal smoking and perinatal outcomes. Early Hum Dev. 2007;83:713–20.PubMedCrossRef
6.
7.
Srikartika VM, O’Leary CM. Pregnancy outcomes of mothers with an alcohol-related diagnosis: a population-based cohort study for the period 1983–2007. BJOG. 2015;122:795–804.PubMedCrossRef
8.
Patra J, Bakker R, Irving H, Jaddoe VW, Malini S, Rehm J. Dose–response relationship between alcohol consumption before and during pregnancy and the risks of low birthweight, preterm birth and small for gestational age (SGA)—a systematic review and meta-analyses. BJOG. 2011;118:1411–21.PubMedCentralPubMedCrossRef
9.
Mamun AA, Najman JM. Birth outcomes associated with cannabis use before and during pregnancy. Pediatric ReseaRch 2012;71.
10.
Addis A, Moretti ME, Ahmed Syed F, Einarson TR, Koren G. Fetal effects of cocaine: an updated meta-analysis. Reprod Toxicol. 2001;15:341–69.PubMedCrossRef
11.
Gouin K, Murphy K, Shah PS. Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. Am J Obstet Gynecol. 2011;204:340.e1–e12.CrossRef
12.
Quesada O, Gotman N, Howell HB, Funai EF, Rounsaville BJ, Yonkers KA. Prenatal hazardous substance use and adverse birth outcomes. J Matern Fetal Neonatal Med. 2012;25:1222–7.PubMedCentralPubMedCrossRef
13.
Almario CV, Seligman NS, Dysart KC, Berghella V, Baxter JK. Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. Am J Obstet Gynecol. 2009;201:326 e1–6.CrossRef
14.
Cnattingius S. The epidemiology of smoking during pregnancy: smoking prevalence, maternal characteristics, and pregnancy outcomes. Nicotine Tob Res. 2004;6 Suppl 2:S125–40.PubMedCrossRef
15.
Wright TE, Schuetter R, Tellei J, Sauvage L. Methamphetamines and pregnancy outcomes. J Addict Med. 2015;9:111–7.PubMedCrossRef
16.
Wouldes TA, Woodward LJ. Maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicol Teratol. 2010;32:406–13.PubMedCrossRef
17.
Hulse GK, Milne E, English DR, Holman CDJ. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction. 1997;92:1571–9.PubMedCrossRef
18.
Pineles BL, Park E, Samet JM. Systematic review and meta-analysis of miscarriage and maternal exposure to tobacco smoke during pregnancy. Am J Epidemiol. 2014;179:807–23.PubMedCentralPubMedCrossRef
19.
Henriksen TB, Hjollund NH, Jensen TK, et al. Alcohol consumption at the time of conception and spontaneous abortion. Am J Epidemiol. 2004;160:661–7.PubMedCrossRef
20.
Avalos LA, Roberts SCM, Kaskutas LA, Block G, Li D-K. Volume and type of alcohol during early pregnancy and the risk of miscarriage. Subst Use Misuse. 2014;49:1437–45.PubMedCentralPubMedCrossRef
21.
22.
Tikkanen M, Nuutila M, Hiilesmaa V, Paavonen J, Ylikorkala O. Prepregnancy risk factors for placental abruption. Acta Obstet Gynecol Scand. 2006;85:40–4.PubMedCrossRef
23.
Horne AW, Brown JK, Nio-Kobayashi J, et al. The association between smoking and ectopic pregnancy: why nicotine is BAD for your fallopian tube. PLoS One. 2014;9, e89400.PubMedCentralPubMedCrossRef
24.
DiFranza JR, Aligne CA, Weitzman M. Prenatal and postnatal environmental tobacco smoke exposure and children’s health. Pediatrics. 2004;113:1007–15.PubMed
25.
Warren KR, Hewitt BG, Thomas JD. Fetal alcohol spectrum disorders: research challenges and opportunities. Alcohol Res Health. 2011;34:4–14.PubMedCentralPubMed
26.
Day NL, Leech SL, Goldschmidt L. The effects of prenatal marijuana exposure on delinquent behaviors are mediated by measures of neurocognitive functioning. Neurotoxicol Teratol. 2011;33:129–36.PubMedCentralPubMedCrossRef
27.
Jaques SC, Kingsbury A, Henshcke P, et al. Cannabis, the pregnant woman and her child: weeding out the myths. J Perinatol. 2014;34:417–24.PubMedCrossRef
28.
Noland JS, Singer LT, Short EJ, et al. Prenatal drug exposure and selective attention in preschoolers. Neurotoxicol Teratol. 2005;27:429–38.PubMedCrossRef
29.
Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2013;12, CD006318.PubMed
30.
31.•
Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA. 2012;307:1934–40. Informative study on neonatal abstinence syndrome and the healthcare costs of opioid use in pregnancy.PubMedCrossRef
32.
Warner TD, Roussos-Ross D, Behnke M. It’s not your mother’s marijuana: effects on maternal-fetal health and the developing child. Clin Perinatol. 2014;41:877–94.PubMedCrossRef
33.
Dyk J, Ramanjam V, Church P, Koren G, Donald K. Maternal methamphetamine use in pregnancy and long-term neurodevelopmental and behavioral deficits in children. J Popul Ther Clin Pharmacol. 2014;21:e185–96.PubMed
34.
Hunt RW, Tzioumi D, Collins E, Jeffery HE. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev. 2008;84:29–35.PubMedCrossRef
35.
Hankin JR. Fetal alcohol syndrome prevention research. Alcohol Res Health. 2002;26:58–65.PubMed
36.
Ludlow JP, Evans SF, Hulse G. Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Aust N Z J Obstet Gynaecol. 2004;44:302–6.PubMedCrossRef
37.
Tuten M, Heil SH, O’Grady KE, Fitzsimons H, Chisolm MS, Jones HE. The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients. Am J Drug Alcohol Abuse. 2009;35:358–63.PubMedCentralPubMedCrossRef
38.
Benningfield MM, Arria AM, Kaltenbach K, et al. Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. Am J Addict. 2010;19:416–21.PubMedCentralPubMedCrossRef
39.
Havens JR, Simmons LA, Shannon LM, Hansen WF. Factors associated with substance use during pregnancy: results from a national sample. Drug Alcohol Depend. 2009;99:89–95.PubMedCrossRef
40.
Hutchins E, Dipietro J. Psychosocial risk factors associated with cocaine use during pregnancy: a case–control study. Obstet Gynecol. 1997;90:142–7.PubMedCrossRef
41.
Mansoor E, Morrow CE, Accornero VH, et al. Longitudinal effects of prenatal cocaine use on mother-child interactions at ages 3 and 5 years. J Dev Behav Pediatr. 2012;33:32–41.PubMedCentralPubMedCrossRef
42.
43.
Higgins PG, Clough DH, Frank B, Wallerstedt C. Changes in health behaviors made by pregnant substance users. Int J Addict. 1995;30:1323–33.PubMed
44.
Suter MA, Mastrobattista J, Sachs M, Aagaard K. Is there evidence for potential harm of electronic cigarette use in pregnancy? Birth Defects Res A Clin Mol Teratol. 2015;103:186–95.PubMedCrossRef
45.
Farquhar B, Mark K, Terplan M, Chisolm MS. Demystifying electronic cigarette use in pregnancy. J Addict Med. 2015;9:157–8.PubMedCrossRef
46.
Baeza-Loya S, Viswanath H, Carter A, et al. Perceptions about e-cigarette safety may lead to e-smoking during pregnancy. Bull Menninger Clin. 2014;78:243–52.PubMedCentralPubMedCrossRef
47.
Ratsch A, Bogossian F. Smokeless tobacco use in pregnancy: an integrative review of the literature. Int J Public Health. 2014;59:599–608.PubMedCrossRef
48.
England LJ, Kim SY, Shapiro-Mendoza CK, et al. Effects of maternal smokeless tobacco use on selected pregnancy outcomes in Alaska Native women: a case–control study. Acta Obstet Gynecol Scand. 2013;92:648–55.PubMedCrossRef
49.
Vardavas CI, Fthenou E, Patelarou E, et al. Exposure to different sources of second-hand smoke during pregnancy and its effect on urinary cotinine and tobacco-specific nitrosamine (NNAL) concentrations. Tob Control. 2013;22:194–200.PubMedCrossRef
50.
Colman GJ, Joyce T. Trends in smoking before, during, and after pregnancy in ten states. Am J Prev Med. 2003;24:29–35.PubMedCrossRef
51.
Heil SH, Herrmann ES, Badger GJ, Solomon LJ, Bernstein IM, Higgins ST. Examining the timing of changes in cigarette smoking upon learning of pregnancy. Prev Med. 2014;68:58–61.PubMedCrossRef
52.
Vaz LR, Leonardi-Bee J, Aveyard P, et al. Factors associated with smoking cessation in early and late pregnancy in the smoking, nicotine, and pregnancy trial: a trial of nicotine replacement therapy. Nicotine Tob Res. 2014;16:381–9.PubMedCentralPubMedCrossRef
53.
DiClemente CC, Dolan-Mullen P, Windsor RA. The process of pregnancy smoking cessation: implications for interventions. Tob Control. 2000;9 Suppl 3:III16–21.PubMedCentralPubMed
54.
Ratner PA, Johnson JL, Bottorff JL. Smoking relapse and early weaning among postpartum women: is there an association? Birth. 1999;26:76–82.PubMedCrossRef
55.
Moore DG, Turner JD, Parrott AC, et al. During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study. J Psychopharmacol. 2010;24:1403–10.PubMedCentralPubMedCrossRef
56.
Goel N, Beasley D, Rajkumar V, Banerjee S. Perinatal outcome of illicit substance use in pregnancy—comparative and contemporary socio-clinical profile in the UK. Eur J Pediatr. 2011;170:199–205.PubMedCrossRef
57.
Yonkers KA, Gotman N, Kershaw T, Forray A, Howell HB, Rounsaville BJ. Screening for prenatal substance use: development of the substance use risk profile-pregnancy scale. Obstet Gynecol. 2010;116:827–33.PubMedCentralPubMedCrossRef
58.
Janisse JJ, Bailey BA, Ager J, Sokol RJ. Alcohol, tobacco, cocaine, and marijuana use: relative contributions to preterm delivery and fetal growth restriction. Subst Abus. 2013;35:60–7.CrossRef
59.
Alshaarawy O, Anthony JC. Month-wise estimates of tobacco smoking during pregnancy for the United States, 2002–2009. Matern Child Health J. 2015;19:1010–5.PubMedCrossRef
60.
Tominey E. Maternal smoking during pregnancy and early child outcomes: Centre for Economic Performance. 2007.
61.
62.
Rua Ede A, Porto ML, Ramos JP, et al. Effects of tobacco smoking during pregnancy on oxidative stress in the umbilical cord and mononuclear blood cells of neonates. J Biomed Sci. 2014;21:105.PubMedCrossRef
63.
Centers for Disease Control and Prevention. Tobacco use. In: Healthy People 2010: understanding and improving health and objectives for improving health. Washington, DC: U.S. Department of Health and Human Services. 2000.
64.
WHO Recommendations for the Prevention and Management of Tobacco Use and Second-Hand Smoke Exposure in Pregnancy. Geneva. 2013.
65.
Inamdar AS, Croucher RE, Chokhandre MK, Mashyakhy MH, Marinho VC. Maternal Smokeless Tobacco Use in Pregnancy and Adverse Health Outcomes in Newborns: A Systematic Review. Nicotine Tob Res. 2014.
66.
Li J, Bo L, Zhang P, et al. Exposure to Nicotine During Pregnancy and Altered Learning and Memory in the Rat Offspring. Nicotine Tob Res. 2014.
67.
Maritz GS. Perinatal exposure to nicotine and implications for subsequent obstructive lung disease. Paediatr Respir Rev. 2013;14:3–8.PubMedCrossRef
68.
Biederman J, Martelon M, Woodworth KY, Spencer TJ, Faraone SV. Is maternal smoking during pregnancy a risk factor for cigarette smoking in offspring? A longitudinal controlled study of ADHD children grown up. J Atten Disord. 2014.
69.
Lotfipour S, Ferguson E, Leonard G, et al. Maternal cigarette smoking during pregnancy predicts drug use via externalizing behavior in two community-based samples of adolescents. Addiction. 2014;109:1718–29.PubMedCrossRef
70.
Mbah AK, Salihu HM, Dagne G, Wilson RE, Bruder K. Exposure to environmental tobacco smoke and risk of antenatal depression: application of latent variable modeling. Arch Womens Ment Health. 2013;16:293–302.PubMedCrossRef
71.
Magee SR, Bublitz MH, Orazine C, et al. The relationship between maternal-fetal attachment and cigarette smoking over pregnancy. Matern Child Health J. 2014;18:1017–22.PubMedCentralPubMedCrossRef
72.
Agboola S, McNeill A, Coleman T, Leonardi BJ. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction. 2010;105:1362–80.PubMedCrossRef
73.
Heckman CJ, Egleston BL, Hofmann MT. Efficacy of motivational interviewing for smoking cessation: a systematic review and meta-analysis. Tob Control. 2010;19:410–6.PubMedCentralPubMedCrossRef
74.
Levitt C, Shaw E, Wong S, Kaczorowski J. Systematic review of the literature on postpartum care: effectiveness of interventions for smoking relapse prevention, cessation, and reduction in postpartum women. Birth. 2007;34:341–7.PubMedCrossRef
75.
Reitzel LR, Vidrine JI, Businelle MS, et al. Preventing postpartum smoking relapse among diverse low-income women: a randomized clinical trial. Nicotine Tob Res. 2010;12:326–35.PubMedCentralPubMedCrossRef
76.
Oncken CA, Kranzler HR. What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy? Nicotine Tob Res. 2009;11:1265–73.PubMedCentralPubMedCrossRef
77.
Essex HN, Parrott S, Wu Q, Li J, Cooper S, Coleman T. Cost-effectiveness of nicotine patches for smoking cessation in pregnancy: a placebo randomized controlled trial (SNAP). Nicotine Tob Res. 2014.
78.
El-Mohandes AA, Windsor R, Tan S, Perry DC, Gantz MG, Kiely M. A randomized clinical trial of trans-dermal nicotine replacement in pregnant African-American smokers. Matern Child Health J. 2013;17:897–906.PubMedCentralPubMedCrossRef
79.
Cooper S, Lewis S, Thornton JG, et al. The SNAP trial: a randomised placebo-controlled trial of nicotine replacement therapy in pregnancy--clinical effectiveness and safety until 2 years after delivery, with economic evaluation. Health Technol Assess. 2014;18:1–128.PubMedCentralCrossRef
80.
Coleman T, Cooper S, Thornton JG, et al. A randomized trial of nicotine-replacement therapy patches in pregnancy. N Engl J Med. 2012;366:808–18.PubMedCrossRef
81.•
Chamberlain C, O’Mara-Eves A, Oliver S, et al. Psychosocial interventions for supporting women to stop smoking in pregnancy. Cochrane Database Syst Rev. 2013;10, Cd001055. This is the latest update of the highly influential meta-analysis of interventions for smoking cessation among pregnant women.PubMedCentralPubMed
82.
Higgins ST, Bernstein IM, Washio Y, et al. Effects of smoking cessation with voucher-based contingency management on birth outcomes. Addiction. 2010;105:2023–30.PubMedCentralPubMedCrossRef
83.
Higgins ST, Washio Y, Heil SH, et al. Financial incentives for smoking cessation among pregnant and newly postpartum women. Preventive Medicine 2012;55, Supplement:S33-S40.
84.•
Ierfino D, Mantzari E, Hirst J, Jones T, Aveyard P, Marteau TM. Financial incentives for smoking cessation in pregnancy: a single-arm intervention study assessing cessation and gaming. Addiction. 2015;110:680–8. This is an effectiveness trial of contingency management for perinatal smoking with extended postpartum follow-up.PubMedCentralPubMedCrossRef
85.
Nguyen KH, Wright RJ, Sorensen G, Subramanian SV. Association between local indoor smoking ordinances in Massachusetts and cigarette smoking during pregnancy: a multilevel analysis. Tob Control. 2013;22:184–9.PubMedCentralPubMedCrossRef
86.
Mejdoubi J, van den Heijkant SC, van Leerdam FJ, Crone M, Crijnen A, HiraSing RA. Effects of nurse home visitation on cigarette smoking, pregnancy outcomes and breastfeeding: a randomized controlled trial. Midwifery. 2014;30:688–95.PubMedCrossRef
87.
Kennedy MG, Genderson MW, Sepulveda AL, et al. Increasing tobacco quitline calls from pregnant African American women: the “one tiny reason to quit” social marketing campaign. J Womens Health. 2013;22:432–8.CrossRef
88.
Higashida Y, Ohashi K. Reduction of tobacco smoke exposure for pregnant passive smokers using feedback of urinary cotinine test results. J Obstet Gynaecol Res. 2014;40:1015–22.PubMedCrossRef
89.
Evans WD, Wallace Bihm J, Szekely D, et al. Initial outcomes from a 4-week follow-up study of the Text4baby program in the military women’s population: randomized controlled trial. J Med Internet Res. 2014;16, e131.PubMedCentralPubMedCrossRef
90.
Kitsantas P, Gaffney KF, Wu H, Kastello JC. Determinants of alcohol cessation, reduction and no reduction during pregnancy. Arch Gynecol Obstet. 2014;289:771–9.PubMedCrossRef
91.
Anderson AE, Hure AJ, Forder PM, Powers J, Kay-Lambkin FJ, Loxton DJ. Risky drinking patterns are being continued into pregnancy: a prospective cohort study. PLoS One. 2014;9, e86171.PubMedCentralPubMedCrossRef
92.
Nykjaer C, Alwan NA, Greenwood DC, et al. Maternal alcohol intake prior to and during pregnancy and risk of adverse birth outcomes: evidence from a British cohort. J Epidemiol Community Health. 2014;68:542–9.PubMedCentralPubMedCrossRef
93.
DeVido J, Bogunovic O, Weiss RD. Alcohol use disorders in pregnancy. Harv Rev Psychiatry. 2015;23:112–21.PubMedCrossRef
94.
Waterman EH, Pruett D, Caughey AB. Reducing fetal alcohol exposure in the United States. Obstet Gynecol Surv. 2013;68:367–78.PubMedCrossRef
95.
Esper LH, Furtado EF. Identifying maternal risk factors associated with Fetal Alcohol Spectrum Disorders: a systematic review. Eur Child Adolesc Psychiatry. 2014;23:877–89.PubMedCrossRef
96.
Fox DJ, Pettygrove S, Cunniff C, et al. Fetal alcohol syndrome among children aged 7–9 years - Arizona, Colorado, and New York, 2010. MMWR Morb Mortal Wkly Rep. 2015;64:54–7.PubMed
97.
Vall O, Salat-Batlle J, Garcia-Algar O. Alcohol consumption during pregnancy and adverse neurodevelopmental outcomes. J Epidemiol Community Health. 2015.
98.
O’Keeffe LM, Greene RA, Kearney PM. The effect of moderate gestational alcohol consumption during pregnancy on speech and language outcomes in children: a systematic review. Syst Rev. 2014;3:1.PubMedCentralPubMedCrossRef
99.
Green CR, Roane J, Hewitt A, et al. Frequent behavioural challenges in children with fetal alcohol spectrum disorder: a needs-based assessment reported by caregivers and clinicians. J Popul Ther Clin Pharmacol. 2014;21:e405–20.PubMed
100.
Bakoyiannis I, Gkioka E, Pergialiotis V, et al. Fetal alcohol spectrum disorders and cognitive functions of young children. Rev Neurosci. 2014;25:631–9.PubMed
101.
Fuglestad AJ, Whitley ML, Carlson SM, et al. Executive functioning deficits in preschool children with Fetal Alcohol Spectrum Disorders. Child Neuropsychol 2014:1–16.
102.
Rangmar J, Hjern A, Vinnerljung B, Stromland K, Aronson M, Fahlke C. Psychosocial outcomes of fetal alcohol syndrome in adulthood. Pediatrics. 2015;135:e52–8.PubMedCrossRef
103.
Lund AE. First-trimester maternal alcohol consumption may lead to oral clefts. J Am Dent Assoc. 2008;139:1452–3.
104.
Qiang M, Wang MW, Elberger AJ. Second trimester prenatal alcohol exposure alters development of rat corpus callosum. Neurotoxicol Teratol. 2002;24:719–32.PubMedCrossRef
105.
Simon KE, Mondares RL, Born DE, Gleason CA. The effects of binge alcohol exposure in the 2nd trimester on the estimated density of cerebral microvessels in near-term fetal sheep. Brain Res. 2008;1231:75–80.PubMedCentralPubMedCrossRef
106.
Li Q, Hankin J, Wilsnack SC, et al. Detection of alcohol use in the second trimester among low-income pregnant women in the prenatal care settings in Jefferson County, Alabama. Alcohol Clin Exp Res. 2012;36:1449–55.PubMedCentralPubMedCrossRef
107.
Diaz MR, Vollmer CC, Zamudio-Bulcock PA, et al. Repeated intermittent alcohol exposure during the third trimester-equivalent increases expression of the GABA(A) receptor delta subunit in cerebellar granule neurons and delays motor development in rats. Neuropharmacology. 2014;79:262–74.PubMedCentralPubMedCrossRef
108.
Topper LA, Valenzuela CF. Effect of repeated alcohol exposure during the third trimester-equivalent on messenger RNA levels for interleukin-1beta, chemokine (C-C motif) ligand 2, and interleukin 10 in the developing rat brain after injection of lipopolysaccharide. Alcohol. 2014;48:773–80.PubMedCrossRef
109.
Washburn SE, Ramadoss J, Chen WJ, Cudd TA. Effects of all three trimester moderate binge alcohol exposure on the foetal hippocampal formation and olfactory bulb. Brain Inj. 2015;29:104–9.PubMedCentralPubMedCrossRef
110.
111.
Osterman RL, Carle AC, Ammerman RT, Gates D. Single-session motivational intervention to decrease alcohol use during pregnancy. J Subst Abuse Treat. 2014;47:10–9.PubMedCentralPubMedCrossRef
112.
Rendall-Mkosi K, Morojele N, London L, Moodley S, Singh C, Girdler-Brown B. A randomized controlled trial of motivational interviewing to prevent risk for an alcohol-exposed pregnancy in the Western Cape, South Africa. Addiction. 2013;108:725–32.PubMedCrossRef
113.
van der Wulp NY, Hoving C, Eijmael K, Candel MJ, van Dalen W, De Vries H. Reducing alcohol use during pregnancy via health counseling by midwives and internet-based computer-tailored feedback: a cluster randomized trial. J Med Internet Res. 2014;16, e274.PubMedCentralPubMedCrossRef
114.
O’Connor MJ, Rotheram-Borus MJ, Tomlinson M, Bill C, LeRoux IM, Stewart J. Screening for fetal alcohol spectrum disorders by nonmedical community workers. J Popul Ther Clin Pharmacol. 2014;21:e442–52.PubMed
115.
Crawford-Williams F, Fielder A, Mikocka-Walus A, Esterman A. A critical review of public health interventions aimed at reducing alcohol consumption and/or increasing knowledge among pregnant women. Drug Alcohol Rev. 2015;34:154–61.PubMedCrossRef
116.
Hanson JD, Jensen J. Importance of social support in preventing alcohol-exposed pregnancies with American Indian communities. J Community Health. 2015;40:138–46.PubMedCrossRef
117.
Wilton G, Moberg DP, Van Stelle KR, Dold LL, Obmascher K, Goodrich J. A randomized trial comparing telephone versus in-person brief intervention to reduce the risk of an alcohol-exposed pregnancy. J Subst Abuse Treat. 2013;45:389–94.PubMedCentralPubMedCrossRef
118.
Chang G. Screening for alcohol and drug use during pregnancy. Obstet Gynecol Clin North Am. 2014;41:205–12.PubMedCrossRef
119.
O’Leary LA, Ortiz L, Montgomery A, et al. Methods for surveillance of fetal alcohol syndrome: The fetal alcohol syndrome surveillance network II (FASSNetII) - Arizona, Colorado, New York, 2009–2014. Birth Defects Res A Clin Mol Teratol. 2015;103:196–202.PubMedCrossRef
120.
Kitsantas P, Gaffney KF, Wu H. Identifying high-risk subgroups for alcohol consumption among younger and older pregnant women. J Perinat Med. 2015;43:43–52.PubMedCrossRef
121.
Cannon MJ, Guo J, Denny CH, et al. Prevalence and characteristics of women at risk for an alcohol-exposed pregnancy (AEP) in the United States: estimates from the National Survey of Family Growth. Matern Child Health J. 2015;19:776–82.PubMedCrossRef
122.
Balachova T, Sobell LC, Agrawal S, et al. Using a single binge drinking question to identify Russian women at risk for an alcohol-exposed pregnancy. Addict Behav. 2015;46:53–7.PubMedCrossRef
123.
Terplan M, Cheng D, Chisolm MS. The relationship between pregnancy intention and alcohol use behavior: an analysis of PRAMS data. J Subst Abuse Treat. 2014;46:506–10.PubMedCrossRef
124.
McDonald SW, Hicks M, Rasmussen C, Nagulesapillai T, Cook J, Tough SC. Characteristics of women who consume alcohol before and after pregnancy recognition in a Canadian sample: a prospective cohort study. Alcohol Clin Exp Res. 2014;38:3008–16.PubMedCrossRef
125.
Brems C, Johnson ME, Metzger JS, Dewane SL. College students’ knowledge about fetal alcohol spectrum disorder. J Popul Ther Clin Pharmacol. 2014;21:e159–66.PubMed
126.
Hill M, Reed K. Pregnancy, breast-feeding, and marijuana: a review article. Obstet Gynecol Surv. 2013;68:710–8.PubMedCrossRef
127.
Ko JY, Farr SL, Tong VT, Creanga AA, Callaghan WM. Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. Am J Obstet Gynecol. 2015.
128.
Martin CE, Longinaker N, Mark K, Chisolm MS, Terplan M. Recent trends in treatment admissions for marijuana use during pregnancy. J Addict Med. 2015;9:99–104.PubMedCrossRef
129.
Mark K, Desai A, Terplan M. Marijuana use and pregnancy: prevalence, associated characteristics, and birth outcomes. Arch Womens Ment Health. 2015.
130.
Administration SAaMHS. The National Survey on Drug Use and Health Report: Substane use among womend urign pregnancy and following childbirth. In: Office of Applied Studies SAaMHSA, ed. Rockville, MD; 2009.
131.
Metz TD, Stickrath EH. Marijuana use in pregnancy and lactation: a review of the evidence. Am J Obstet Gynecol. 2015.
132.
Tzilos G, Hess L, Kao JC, Zlotnick C. Characteristics of perinatal women seeking treatment for marijuana abuse in a community-based clinic. Arch Womens Ment Health. 2013;16:333–7.PubMedCentralPubMedCrossRef
133.
Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol. 1994;62:92–9.PubMedCrossRef
134.
Carroll KM, Nich C, Lapaglia DM, Peters EN, Easton CJ, Petry NM. Combining cognitive behavioral therapy and contingency management to enhance their effects in treating cannabis dependence: less can be more, more or less. Addiction. 2012;107:1650–9.PubMedCentralPubMedCrossRef
135.
Hoch E, Noack R, Henker J, et al. Efficacy of a targeted cognitive-behavioral treatment program for cannabis use disorders (CANDIS). Eur Neuropsychopharmacol. 2012;22:267–80.PubMedCrossRef
136.
Copeland J, Swift W, Roffman R, Stephens R. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treat. 2001;21:55–64. discussion 5–6.PubMedCrossRef
137.
Hoch E, Bühringer G, Pixa A, et al. CANDIS treatment program for cannabis use disorders: findings from a randomized multi-site translational trial. Drug Alcohol Depend. 2014;134:185–93.PubMedCrossRef
138.
Bhuvaneswar CG, Chang G, Epstein LA, Stern TA. Cocaine and opioid use during pregnancy: prevalence and management. Prim Care Companion J Clin Psychiatry. 2008;10:59–65.PubMedCentralPubMedCrossRef
139.
Chaplin TM, Freiburger MB, Mayes LC, Sinha R. Prenatal cocaine exposure, gender, and adolescent stress response: a prospective longitudinal study. Neurotoxicol Teratol. 2010;32:595–604.PubMedCentralPubMedCrossRef
140.
Bandstra ES, Vogel AL, Morrow CE, Xue L, Anthony JC. Severity of prenatal cocaine exposure and child language functioning through age seven years: a longitudinal latent growth curve analysis. Subst Use Misuse. 2004;39:25–59.PubMedCentralPubMedCrossRef
141.
Frank DA, Augustyn M, Knight WG, Pell T, Zuckerman B. Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. JAMA. 2001;285:1613–25.PubMedCentralPubMedCrossRef
142.
Hull L, May J, Farrell-Moore D, Svikis DS. Treatment of cocaine abuse during pregnancy: translating research to clinical practice. Curr Psychiatry Rep. 2010;12:454–61.PubMedCrossRef
143.
144.
Richardson GA, Goldschmidt L, Larkby C, Day NL. Effects of prenatal cocaine exposure on adolescent development. Neurotoxicol Teratol. 2015;49:41–8.PubMedCrossRef
145.
Richardson GA, Goldschmidt L, Larkby C, Day NL. Effects of prenatal cocaine exposure on child behavior and growth at 10 years of age. Neurotoxicol Teratol. 2013;40:1–8.PubMedCrossRef
146.
De Genna N, Goldschmidt L, Richardson GA. Prenatal cocaine exposure and age of sexual initiation: direct and indirect effects. Drug Alcohol Depend. 2014;145:194–200.PubMedCrossRef
147.
Richardson GA, Larkby C, Goldschmidt L, Day NL. Adolescent initiation of drug use: effects of prenatal cocaine exposure. J Am Acad Child Adolesc Psychiatry. 2013;52:37–46.PubMedCentralPubMedCrossRef
148.
Bessa MA, Mitsuhiro SS, Chalem E, Barros MM, Guinsburg R, Laranjeira R. Underreporting of use of cocaine and marijuana during the third trimester of gestation among pregnant adolescents. Addict Behav. 2010;35:266–9.PubMedCrossRef
149.•
Terplan M, Ramanadhan S, Locke A, Longinaker N, Lui S. Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions. Cochrane Database Syst Rev. 2015;4, Cd006037. This is the most recent critical review of available behavioral interventions for illicit substance use.PubMed
150.
Schottenfeld RS, Moore B, Pantalon MV. Contingency management with community reinforcement approach or twelve-step facilitation drug counseling for cocaine dependent pregnant women or women with young children. Drug Alcohol Depend. 2011;118:48–55.PubMedCrossRef
151.
Yonkers KA, Forray A, Nich C, et al. Progesterone reduces cocaine use in postpartum women with a cocaine use disorder: a randomized, double-blind study. Lancet Psychiatry. 2014;1:360–7.PubMedCentralPubMedCrossRef
152.
Wouldes TA, LaGasse LL, Derauf C, et al. Co-morbidity of substance use disorder and psychopathology in women who use methamphetamine during pregnancy in the US and New Zealand. Drug Alcohol Depend. 2013;127:101–7.PubMedCentralPubMedCrossRef
153.
McDonnell-Dowling K, Donlon M, Kelly JP. Methamphetamine exposure during pregnancy at pharmacological doses produces neurodevelopmental and behavioural effects in rat offspring. Int J Dev Neurosci. 2014;35:42–51.PubMedCrossRef
154.
Gorman MC, Orme KS, Nguyen NT, Kent EJ, 3rd, Caughey AB. Outcomes in pregnancies complicated by methamphetamine use. Am J Obstet Gynecol 2014;211:429 e1-7.
155.
Jones HE, Myers B, O’Grady KE, Gebhardt S, Theron GB, Wechsberg WM. Initial feasibility and acceptability of a comprehensive intervention for methamphetamine-using pregnant women in South Africa. Psychiatry J. 2014;2014:929767.PubMedCentralPubMedCrossRef
156.
Jones HE, O’Grady KE, Tuten M. Reinforcement-based treatment improves the maternal treatment and neonatal outcomes of pregnant patients enrolled in comprehensive care treatment. Am J Addict. 2011;20:196–204.PubMedCentralPubMedCrossRef
157.
White SJ, Hendrickson HP, Atchley WT, et al. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy. Drug Metab Dispos. 2014;42:1285–91.PubMedCentralPubMedCrossRef
158.
Jones HE, Heil SH, Tuten M, et al. Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes. Drug Alcohol Depend. 2013;131:271–7.PubMedCentralPubMedCrossRef
159.
Chisolm MS, Tuten M, Brigham EC, Strain EC, Jones HE. Relationship between cigarette use and mood/anxiety disorders among pregnant methadone-maintained patients. Am J Addict. 2009;18:422–9.PubMedCentralPubMedCrossRef
160.
Bateman BT, Hernandez-Diaz S, Rathmell JP, et al. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiology. 2014;120:1216–24.PubMedCentralPubMedCrossRef
161.
162.
Jones HE, O’Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008;17:372–86.PubMedCrossRef
163.
164.•
Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207. This critical review examines the available data on opiate maintenance therapy in pregnancy.PubMed
165.
Jones HE, Haug N, Silverman K, Stitzer M, Svikis D. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend. 2001;61:297–306.PubMedCrossRef
166.
O’Connor AB, Collett A, Alto WA, O’Brien LM. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy. J Midwifery Womens Health. 2013;58:383–8.PubMedCrossRef
167.
Welle-Strand GK, Skurtveit S, Jansson LM, Bakstad B, Bjarko L, Ravndal E. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr. 2013;102:1060–6.PubMed
168.
Mikkola K, Ritari N, Tommiska V, et al. Neurodevelopmental outcome at 5 years of age of a national cohort of extremely low birth weight infants who were born in 1996–1997. Pediatrics. 2005;116:1391–400.PubMedCrossRef
169.
Hayatbakhsh MR, Kingsbury AM, Flenady V, Gilshenan KS, Hutchinson DM, Najman JM. Illicit drug use before and during pregnancy at a tertiary maternity hospital 2000–2006. Drug Alcohol Rev. 2011;30:181–7.PubMedCrossRef
170.
Akerman SC, Brunette MF, Green AI, Goodman DJ, Blunt HB, Heil SH. Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review. J Subst Abuse Treat. 2015;52:40–7.PubMedCrossRef
171.
Bloch M, Parascandola M. Tobacco use in pregnancy: a window of opportunity for prevention. Lancet Glob Health. 2014;2:e489–90.PubMedCrossRef
172.
Field M, Cox WM. Attentional bias in addictive behaviors: a review of its development, causes, and consequences. Drug Alcohol Depend. 2008;97:1–20.PubMedCrossRef
Metadata
Title
Substance Use in the Perinatal Period
Authors
Ariadna Forray
Dawn Foster
Publication date
01-11-2015
Publisher
Springer US
Published in
Current Psychiatry Reports / Issue 11/2015
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-015-0626-5

Other articles of this Issue 11/2015

Current Psychiatry Reports 11/2015 Go to the issue

Women's Mental Health (CN Epperson, Section Editor)

Premenstrual Dysphoric Disorder: Epidemiology and Treatment

Eating Disorders (C Grilo, Section Editor)

Deconstructing “Atypical” Eating Disorders: an Overview of Emerging Eating Disorder Phenotypes

Psychiatry in the Digital Age (JS Luo, Section Editor)

Telepsychiatry Today

Psychiatry in the Digital Age (JS Luo, Section Editor)

Blogging and Social Media for Mental Health Education and Advocacy: a Review for Psychiatrists

Women's Mental Health (CN Epperson, Section Editor)

GABAA Receptor-Modulating Steroids in Relation to Women’s Behavioral Health

Women's Mental Health (CN Epperson, Section Editor)

The Preeminence of Early Life Trauma as a Risk Factor for Worsened Long-Term Health Outcomes in Women